National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England

Tender description

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 25: Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 22: Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 1: Atezolizumab - Lot 1 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Bevacizumab (Avastin) - Lot 2 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Bevacizumab (Zirabev) - Lot 3 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 4: Bevacizumab (Aybintio) - Lot 4 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 5: Bleomycin - Lot 5 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 11: Cyclophosphamide Bags - Lot 11 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 33: Obinutuzumab - Lot 33 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 38: Pemetrexed - Lot 38 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 17: Fludarabine Bags - Lot 17 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 27: Ganciclovir - Lot 27 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 31: Methotrexate - Lot 31 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 23: Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 19: Fluorouracil Bags - Lot 19 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 6: Bortezomib - Lot 6 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 39: Pertuzumab - Lot 39 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 7: Carboplatin - Lot 7 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 36: Panitumumab - Lot 36 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 50: Vinorelbine - Lot 50 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 21: Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 30: Irinotecan - Lot 30 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 16: Fludarabine Syringes - Lot 16 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 47: Trastuzumab (Trasimera) - Lot 47 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 24: Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 37: Pembrolizumab - Lot 37 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 8: Cetuximab - Lot 8 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 13: Docetaxel - Lot 13 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 18: Fluorouracil Syringes - Lot 18 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 14: Doxorubicin - Lot 14 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 26: Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 12: Cytarabine - Lot 12 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 32: Nivolumab - Lot 32 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 10: Cyclophosphamide Syringes - Lot 10 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 44: Trastuzumab (Herzuma) - Lot 44 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 34: Oxaliplatin - Lot 34 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 48: Vinblastine - Lot 48 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 9: Cisplatin - Lot 9 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 28: Gemcitabine - Lot 28 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 49: Vincristine - Lot 49 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 43: Trastuzumab (Herceptin) - Lot 43 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 46: Trastuzumab (Ontruzant) - Lot 46 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 15: Epirubicin - Lot 15 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Lot 42: Rituximab (Truxima) - Lot 42 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 40: Rituximab (Mabthera) - Lot 40 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 41: Rituximab (Rixathon) - Lot 41 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 35: Paclitaxel - Lot 35 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 45: Trastuzumab (Kanjinti) - Lot 45 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 20: Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20 NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.